12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anti-PD-L1: Phase I data

Data from 160 evaluable patients with advanced solid tumors in the open-label, U.S. Phase I MDX1105-01 trial showed that IV BMS-936559 produced an objective response in 9 (17%) melanoma patients (n=52), 5 (10%) non-small cell lung cancer (NSCLC) patients (n=49), 1 (6%) ovarian cancer patient (n=17) and 2 (12%) renal cell carcinoma (RCC) patients (n=17). There were no objective responses in patients with...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >